-+ 0.00%
-+ 0.00%
-+ 0.00%

Incannex Completes Phase 2 Enrollment for Sleep Apnea Drug Trial Targeting Better Rest

Benzinga·04/03/2025 11:32:23
Listen to the news

Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new oral combination medicines, today announced that the Company has completed Phase 2 patient enrollment in the global Phase 2/3 RePOSA study of IHL-42X for the treatment of Obstructive Sleep Apnea (OSA). IHL-42X is an oral fixed dose combination medicine designed to reduce the incidence of interruptions to breathing during sleep and improve sleep quality.